Question Bank › Proof-point cadence

Proof-point cadence

Proof-point cadence: the last promised marker just landed, and the next one is already on the clock

Calls Tested
345
Answered YES
24
Hit Rate
7%
rare by design

Supernus Pharmaceuticals, Inc. (SUPN) — this company's answers

NO on the Q3 2016 call 2016-11-18 D
The model's full reasoning — Q3 2016 call → NOWe need to determine if management presents progress as a live, checkable sequence of proof points with both a marker just delivered and a next marker named and near. Let's examine the transcript. Management discusses various items: product sales growth, FDA tentative approval for Trokendi XR migraine indication, pipeline updates for SPN-810 and SPN-812, IP litigation, business development. Specifically, for SPN-812, they announced positive top-line results from Phase 2b trial. That is a concrete milestone just delivered. They also say they plan to have an end of Phase 2 meeting with FDA, after which they will initiate Phase 3 clinical testing. That is a next step, but is it near-term? They don't give specific timing. They say "We plan to have an end of Phase 2 meeting with the FDA, after which we will initiate Phase 3 clinical testing." No timing given. Also, they mention that R&D expenses for 2017 will depend on timing of initiation of two Phase 3 studies for SPN-812, but no specific date. For SPN-810, they discuss enrollment continues, steps taken to improve enrollment, but they also say enrollment expected to continue into 2017, and data likely in 2018. That is not near-term within a year? Actually, they say "most likely, of course, the data would be in 2018" - that's more than a year away. Also, they are not presenting a just-delivered marker for SPN-810; they are explaining delays and improvements. For Trokendi XR, they got tentative approval for migraine indication, but they say "We continue to prepare, and will be ready to launch the migraine indication soon after receiving full FDA approval." That is a next step, but full FDA approval is not yet obtained, and timing is not specified. They don't say when they expect full approval. The call also discusses the restatement of financials due to accounting issue, which is a negative event, not a proof point. Overall, management does not present a clear sequence of "just delivered" and "next near-term" markers. The SPN-812 Phase 2b results are a delivered marker, but the next step (Phase 3 initiation) is not given a specific near-term timing. The migraine launch is contingent on full FDA approval, which is not yet in hand. The SPN-810 is delayed. Thus, the answer is NO.

← Back to the full SUPN analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management present the company's progress as a LIVE, CHECKABLE SEQUENCE OF PROOF POINTS — with BOTH of the following present in management's own words as one coherent posture? (1) A MARKER JUST DELIVERED. Management reports that a specific, concrete operational step it had previously set out to accomplish has JUST been completed or reached in the recent period — something real and verifiable that happened (for example: a facility, line, or site brought online; a product, program, or service launched or shipped; a certification, approval, qualification, or acceptance obtained; a first delivery, first production, first customer, or go-live achieved; a ramp, rollout, conversion, or expansion reaching a defined stage; an integration, build, or transition completed). Management should treat this as a checkpoint passed on a path it had already described or committed to — not merely a good financial result, and not routine activity every quarter contains. (2) THE NEXT MARKER IS NAMED AND NEAR. Management also identifies the NEXT concrete step on that same forward path and anchors it in the near term (roughly within the coming year) with at least approximate timing — what specifically is supposed to happen next and when — presented as scheduled, in motion, or already being executed rather than as an aspiration, and specific enough that an observer could later tell whether it happened. The essence is ONE phenomenon, in whatever form fits the industry: a company moving through an execution sequence in real time — the last checkpoint just cleared, the next checkpoint already on the clock — with management inviting investors to track it step by step, and treating this progression (rather than general market conditions) as what is driving where the company is headed. Answer NO if the call reports only completed accomplishments with no specific near-term next step attached to the same path. NO if management only promises future milestones without any recently completed checkpoint behind them. NO if the only 'delivery' is beating financial guidance or reporting strong numbers, with no operational checkpoint passed. NO if the completed and upcoming steps are routine business-as-usual for this company (ordinary seasonal openings, standard product refreshes, normal maintenance) that management does not present as advancing the company's trajectory. NO if the next step is vague, undated, distant, or contingent on financing, approvals, or decisions not yet in hand. NO if management is chiefly explaining delays, misses, or resets of previously promised milestones. NO if the sequence is assembled only in an analyst's question or summary that management does not itself adopt. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
CMPS COMPASS Pathways plc Q3 2023 2023-11-04 F
VRE Veris Residential, Inc. Q4 2022 2023-02-22 D
ADPT Adaptive Biotechnologies Corporation Q4 2022 2023-02-14 C+
HIW Highwoods Properties, Inc. Q4 2022 2023-02-08 B
TCBI Texas Capital Bancshares, Inc. Q2 2021 2021-07-21 F
CUBI Customers Bancorp, Inc. Q3 2018 2018-10-26 C+
AU AngloGold Ashanti's Q2 2018 2018-08-20 B
XOM Exxon Mobil Corporation Q2 2018 2018-07-27 C
MKC McCormick & Company, Incorporated Q2 2018 2018-06-28 C+
CLMT Calumet Specialty Products Partners, L.P Q1 2018 2018-05-16 C+
ATI Allegheny Technologies Incorporated Q1 2018 2018-04-24 B
SCVL Shoe Carnival, Inc. Q4 2017 2018-03-27 C+
UPLD Upland Software, Inc. Q4 2017 2018-03-08 C+
ITCI Intra-Cellular Therapies, Inc. Q4 2017 2018-03-01 D
INSM Insmed Incorporated Q4 2017 2018-02-23 B
AOSL Alpha and Omega Semiconductor Limited Q2 2018 2018-02-07 B
SBSI Southside Bancshares, Inc. Q4 2017 2018-02-06 A
CPK Chesapeake Utilities Corporation Q3 2017 2017-11-10 A
HOLX Hologic, Inc. Q4 2017 2017-11-08 D
IBTX Independent Bank Group, Inc. Q3 2017 2017-10-24 A
MXL MaxLinear, Inc. Q2 2017 2017-08-08 C+
LIND Lindblad Expeditions Holdings, Inc. Q2 2017 2017-08-06 C
BP BP p.l.c. Q4 2016 2017-02-07 B+
RCL Royal Caribbean Cruises Ltd. Q1 2016 2016-04-29 C+

How the model reasoned

XOM · Q2 2018 → YESThe question is whether management presents the company's progress as a LIVE, CHECKABLE SEQUENCE OF PROOF POINTS with both a marker just delivered and the next marker named and near. YES Management presents a live, checkable sequence of proof points. In Neil Chapman's remarks, he explicitly notes that the Coral Floating LNG project is "progressing on schedule" and that "fabrication of the hull is expected to start in the third quarter of this year" — a concrete, near-term operational checkpoint 3–4 months away. Immediately prior, he states that "earlier this month, we announced that the development plan for the first phase has been submitted," treating that submission as the just-completed marker on the same path. He anchors the next step as "targeting final investment decision in 2019" with 2024 first LNG, presented as scheduled and already in motion rather than aspirational. This forms one coherent posture: the company is executing a verifiable execution sequence on the Mozambique LNG opportunity, with the development-plan submission just cleared and FID locked for 2019. Other examples (Baytown ethane cracker operations begun yesterday; 50 new Permian wells brought to sales in the quarter) exist, but the Mozambique LNG thread satisfies both required elements on a single forward path. No other elements (financial beats, routine maintenance, or analyst questions) are used to construct the sequence.
MKC · Q2 2018 → YESThe question is whether management presents the company's progress as a LIVE, CHECKABLE SEQUENCE OF PROOF POINTS with both a marker just delivered and the next marker named and near. YES The transcript shows management framing the Frank's and French's integration as a completed checkpoint ("With the acquisition and integration complete"), then immediately naming and anchoring the next concrete steps on the same path — such as launching the first dedicated mustard campaign in the U.S. (kicked off this week during the call) and 2018 U.S. national TV advertising for Frank's in the second half — as scheduled, in-motion activities that will drive further growth. This is presented as one coherent execution sequence rather than isolated results. Other elements like distribution gains and summer grilling promotions are tied directly to this progression. No routine or vague items qualify; 2018 advertising and marketing acceleration are explicitly tied to the post-integration trajectory.
CMPS · Q3 2023 → YESThe question is whether management presents the company's progress as a LIVE, CHECKABLE SEQUENCE OF PROOF POINTS with both a marker just delivered and the next marker named and near. YES The transcript shows management framing progress as a live execution sequence: the open-label PTSD Phase II study has just reached full recruitment (a concrete checkpoint passed), and they explicitly name the next marker — top-line readout this year — as the immediate follow-on step already in motion and scheduled within the coming months. This is presented as part of the same forward trajectory they are tracking, alongside the TRD Phase III where site initiations (3/4 of COMP005) are described as continuing to advance toward the summer 2024 readout.

More from the question bank

Scarcity premium: the thing the company sellLocus of control flipSomeone else already paid for the growthBetting on one customer's rampCorrecting the record with current factsCheck it yourselvesAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.